Retroperitoneal fibrosis caused by pergolide in a patient with Parkinson's disease

Bilici A., Karadag B., Doventas A., Erdincler D., Cetinkaya S., Ogut G., ...More

NETHERLANDS JOURNAL OF MEDICINE, vol.62, no.10, pp.389-392, 2004 (SCI-Expanded) identifier identifier identifier

  • Publication Type: Article / Article
  • Volume: 62 Issue: 10
  • Publication Date: 2004
  • Journal Name: NETHERLANDS JOURNAL OF MEDICINE
  • Journal Indexes: Science Citation Index Expanded (SCI-EXPANDED), Scopus
  • Page Numbers: pp.389-392
  • Istanbul University Affiliated: Yes

Abstract

Retroperitoneal fibrosis (RPF) is an uncommon disorder that may cause ureteric obstruction with renal damage. Pergolide, a dopaminergic agonist used in the treatment of Parkinson's disease, has rarely been related to the development of RPF. We report on a 78-year-old woman with Parkinson's disease who presented with hydroureteronephrosis and developed RPF and serosal fibrosis during treatment with pergolide. Following discontinuation of pergolide therapy and placement of a double-J stent, her renal function improved. Inflammatory markers returned to normal limits within two months and the retroperitoneal fibrotic mass became smaller.